Skip to main content

Advertisement

SpringerLink
Log in

Adiponectin: a key playmaker adipocytokine in non-alcoholic fatty liver disease

  • Review Article
  • Published:
Clinical and Experimental Medicine Aims and scope Submit manuscript

Abstract

Non-alcoholic fatty liver disease (NAFLD) is the hepatic manifestation of metabolic syndrome and can progress to cirrhosis, liver failure, and hepatocellular carcinoma. In the last two decades, the prevalence of NAFLD has been growing in most developed countries, mainly as a consequence of its close association with obesity and diabetes mellitus. The exact pathogenesis of NAFLD and especially the mechanisms leading to disease progression have not been completely understood. Adipocytes produce and secrete several bioactive substances known as adipocytokines which are implicated in the pathogenesis of the disease. Among them, adiponectin is an insulin-sensitizing adipocytokine possessing multiple beneficial effects on obesity-related medical complication. This review focuses on the role of adiponectin in NAFLD pathogenesis and its potential use as a diagnostic tool but also as therapeutic target for NAFLD management.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Sanyal AJ (2002) AGA technical review on nonalcoholic fatty liver disease. Gastroenterology 123:1705–1725

    PubMed  Google Scholar 

  2. Farrell GC, Larter CZ (2006) Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology 43(2 Suppl 1):S99–S112. doi:10.1002/hep.20973

    CAS  PubMed  Google Scholar 

  3. Marchesini G, Bugianesi E, Forlani G, Cerrelli F, Lenzi M, Manini R, Natale S, Vanni E, Villanova N, Melchionda N, Rizzetto M (2003) Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 37:917–923. doi:10.1053/jhep.2003.50161

    PubMed  Google Scholar 

  4. Adams LA, Angulo P (2005) Recent concepts in non-alcoholic fatty liver disease. Diabet Med 22:1129–1133. doi:10.1111/j.1464-5491.2005.01748.x

    CAS  PubMed  Google Scholar 

  5. Browning JD, Szczepaniak LS, Dobbins R, Nuremberg P, Horton JD, Cohen JC, Grundy SM, Hobbs HH (2004) Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 40:1387–1395. doi:10.1002/hep.20466

    PubMed  Google Scholar 

  6. Bellentani S, Saccoccio G, Masutti F, Croce LS, Brandi G, Sasso F, Cristanini G, Tiribelli C (2000) Prevalence of and risk factors for hepatic steatosis in Northern Italy. Ann Intern Med 132:112–117

    CAS  PubMed  Google Scholar 

  7. Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ (1999) Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 116:1413–1419

    CAS  PubMed  Google Scholar 

  8. Ahima RS (2007) Insulin resistance: cause or consequence of nonalcoholic steatohepatitis? Gastroenterology 132:444–446. doi:10.1053/j.gastro.2006.11.048

    CAS  PubMed  Google Scholar 

  9. Antuna-Puente B, Feve B, Fellahi S, Bastard JP (2008) Adipokines: the missing link between insulin resistance and obesity. Diabetes Metab 34:2–11. doi:10.1016/j.diabet.2007.09.004

    CAS  PubMed  Google Scholar 

  10. Kamada Y, Takehara T, Hayashi N (2008) Adipocytokines and liver disease. J Gastroenterol 43:811–822. doi:10.1007/s00535-008-2213-6

    CAS  PubMed  Google Scholar 

  11. Kershaw EE, Flier JS (2004) Adipose tissue as an endocrine organ. J Clin Endocrinol Metab 89:2548–2556. doi:10.1210/jc.2004-0395

    CAS  PubMed  Google Scholar 

  12. Musso G, Gambino R, Durazzo M, Biroli G, Carello M, Faga E, Pacini G, De Michieli F, Rabbione L, Premoli A, Cassader M, Pagano G (2005) Adipokines in NASH: postprandial lipid metabolism as a link between adiponectin and liver disease. Hepatology 42:1175–1183. doi:10.1002/hep.20896

    CAS  PubMed  Google Scholar 

  13. Jarrar MH, Baranova A, Collantes R, Ranard B, Stepanova M, Bennett C, Fang Y, Elariny H, Goodman Z, Chandhoke V, Younossi ZM (2008) Adipokines and cytokines in non-alcoholic fatty liver disease. Aliment Pharmacol Ther 27:412–421. doi:10.1111/j.1365-2036.2007.03586.x

    CAS  PubMed  Google Scholar 

  14. Carter-Kent C, Zein NN, Feldstein AE (2008) Cytokines in the pathogenesis of fatty liver and disease progression to steatohepatitis: implications for treatment. Am J Gastroenterol 103:1036–1042. doi:10.1111/j.1572-0241.2007.01709.x

    CAS  PubMed  Google Scholar 

  15. Trujillo ME, Scherer PE (2005) Adiponectin–journey from an adipocyte secretory protein to biomarker of the metabolic syndrome. J Intern Med 257:167–175. doi:10.1111/j.1365-2796.2004.01426.x

    CAS  PubMed  Google Scholar 

  16. Cnop M, Havel PJ, Utzschneider KM, Carr DB, Sinha MK, Boyko EJ, Retzlaff BM, Knopp RH, Brunzell JD, Kahn SE (2003) Relationship of adiponectin to body fat distribution, insulin sensitivity and plasma lipoproteins: evidence for independent roles of age and sex. Diabetologia 46:459–469. doi:10.1007/s00125-003-1074-z

    CAS  PubMed  Google Scholar 

  17. Ayonrinde OT, Olynyk JK, Beilin LJ, Mori TA, Pennell CE, de Klerk N, Oddy WH, Shipman P, Adams LA (2011) Gender-specific differences in adipose distribution and adipocytokines influence adolescent nonalcoholic fatty liver disease. Hepatology 53:800–809. doi:10.1002/hep.24097

    CAS  PubMed  Google Scholar 

  18. Khan UI, Wang D, Sowers MR, Mancuso P, Everson-Rose SA, Scherer PE, Wildman RP (2012) Race-ethnic differences in adipokine levels: the Study of Women’s Health Across the Nation (SWAN). Metabolism. doi:10.1016/j.metabol.2012.02.005

    PubMed Central  PubMed  Google Scholar 

  19. Halberg N, Schraw TD, Wang ZV, Kim JY, Yi J, Hamilton MP, Luby-Phelps K, Scherer PE (2009) Systemic fate of the adipocyte-derived factor adiponectin. Diabetes 58:1961–1970. doi:10.2337/db08-1750

    PubMed Central  PubMed  Google Scholar 

  20. Waki H, Yamauchi T, Kamon J, Ito Y, Uchida S, Kita S, Hara K, Hada Y, Vasseur F, Froguel P, Kimura S, Nagai R, Kadowaki T (2003) Impaired multimerization of human adiponectin mutants associated with diabetes. Molecular structure and multimer formation of adiponectin. J Biol Chem 278:40352–40363. doi:10.1074/jbc.M300365200

    CAS  PubMed  Google Scholar 

  21. Wang Y, Lam KS, Yau MH, Xu A (2008) Post-translational modifications of adiponectin: mechanisms and functional implications. Biochem J 409:623–633. doi:10.1042/BJ20071492

    CAS  PubMed  Google Scholar 

  22. Ziemke F, Mantzoros CS (2010) Adiponectin in insulin resistance: lessons from translational research. Am J Clin Nutr 91:258S–261S. doi:10.3945/ajcn.2009.28449C

    CAS  PubMed Central  PubMed  Google Scholar 

  23. Bobbert T, Rochlitz H, Wegewitz U, Akpulat S, Mai K, Weickert MO, Mohlig M, Pfeiffer AF, Spranger J (2005) Changes of adiponectin oligomer composition by moderate weight reduction. Diabetes 54:2712–2719

    CAS  PubMed  Google Scholar 

  24. Salani B, Briatore L, Andraghetti G, Adami GF, Maggi D, Cordera R (2006) High-molecular weight adiponectin isoforms increase after biliopancreatic diversion in obese subjects. Obesity 14:1511–1514. doi:10.1038/oby.2006.174

    CAS  PubMed  Google Scholar 

  25. Swarbrick MM, Austrheim-Smith IT, Stanhope KL, Van Loan MD, Ali MR, Wolfe BM, Havel PJ (2006) Circulating concentrations of high-molecular-weight adiponectin are increased following Roux-en-Y gastric bypass surgery. Diabetologia 49:2552–2558. doi:10.1007/s00125-006-0452-8

    CAS  PubMed  Google Scholar 

  26. Tsao TS, Murrey HE, Hug C, Lee DH, Lodish HF (2002) Oligomerization state-dependent activation of NF-kappa B signaling pathway by adipocyte complement-related protein of 30 kDa (Acrp30). J Biol Chem 277:29359–29362. doi:10.1074/jbc.C200312200

    CAS  PubMed  Google Scholar 

  27. Bluher M, Brennan AM, Kelesidis T, Kratzsch J, Fasshauer M, Kralisch S, Williams CJ, Mantzoros CS (2007) Total and high-molecular weight adiponectin in relation to metabolic variables at baseline and in response to an exercise treatment program: comparative evaluation of three assays. Diabetes Care 30:280–285. doi:10.2337/dc06-1362

    PubMed  Google Scholar 

  28. Kadowaki T, Yamauchi T (2005) Adiponectin and adiponectin receptors. Endocr Rev 26:439–451. doi:10.1210/er.2005-0005

    CAS  PubMed  Google Scholar 

  29. Yamauchi T, Nio Y, Maki T, Kobayashi M, Takazawa T, Iwabu M, Okada-Iwabu M, Kawamoto S, Kubota N, Kubota T, Ito Y, Kamon J, Tsuchida A, Kumagai K, Kozono H, Hada Y, Ogata H, Tokuyama K, Tsunoda M, Ide T, Murakami K, Awazawa M, Takamoto I, Froguel P, Hara K, Tobe K, Nagai R, Ueki K, Kadowaki T (2007) Targeted disruption of AdipoR1 and AdipoR2 causes abrogation of adiponectin binding and metabolic actions. Nat Med 13:332–339. doi:10.1038/nm1557

    CAS  PubMed  Google Scholar 

  30. Tomita K, Oike Y, Teratani T, Taguchi T, Noguchi M, Suzuki T, Mizutani A, Yokoyama H, Irie R, Sumimoto H, Takayanagi A, Miyashita K, Akao M, Tabata M, Tamiya G, Ohkura T, Hibi T (2008) Hepatic AdipoR2 signaling plays a protective role against progression of nonalcoholic steatohepatitis in mice. Hepatology 48:458–473. doi:10.1002/hep.22365

    CAS  PubMed  Google Scholar 

  31. Yamauchi T, Kamon J, Waki H, Terauchi Y, Kubota N, Hara K, Mori Y, Ide T, Murakami K, Tsuboyama-Kasaoka N, Ezaki O, Akanuma Y, Gavrilova O, Vinson C, Reitman ML, Kagechika H, Shudo K, Yoda M, Nakano Y, Tobe K, Nagai R, Kimura S, Tomita M, Froguel P, Kadowaki T (2001) The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 7:941–946. doi:10.1038/90984

    CAS  PubMed  Google Scholar 

  32. Yamauchi T, Kamon J, Minokoshi Y, Ito Y, Waki H, Uchida S, Yamashita S, Noda M, Kita S, Ueki K, Eto K, Akanuma Y, Froguel P, Foufelle F, Ferre P, Carling D, Kimura S, Nagai R, Kahn BB, Kadowaki T (2002) Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 8:1288–1295. doi:10.1038/nm788

    CAS  PubMed  Google Scholar 

  33. Yamauchi T, Kamon J, Ito Y, Tsuchida A, Yokomizo T, Kita S, Sugiyama T, Miyagishi M, Hara K, Tsunoda M, Murakami K, Ohteki T, Uchida S, Takekawa S, Waki H, Tsuno NH, Shibata Y, Terauchi Y, Froguel P, Tobe K, Koyasu S, Taira K, Kitamura T, Shimizu T, Nagai R, Kadowaki T (2003) Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 423:762–769. doi:10.1038/nature01705

    CAS  PubMed  Google Scholar 

  34. Vincent MF, Marangos PJ, Gruber HE, Van den Berghe G (1991) Inhibition by AICA riboside of gluconeogenesis in isolated rat hepatocytes. Diabetes 40:1259–1266

    CAS  PubMed  Google Scholar 

  35. Browning JD, Horton JD (2004) Molecular mediators of hepatic steatosis and liver injury. J Clin Invest 114:147–152. doi:10.1172/JCI22422

    CAS  PubMed Central  PubMed  Google Scholar 

  36. Pyper SR, Viswakarma N, Yu S, Reddy JK (2010) PPARalpha: energy combustion, hypolipidemia, inflammation and cancer. Nucl Recept Signal 8:e002. doi:10.1621/nrs.08002

    PubMed Central  PubMed  Google Scholar 

  37. Hu XQ, Wang YM, Wang JF, Xue Y, Li ZJ, Nagao K, Yanagita T, Xue CH (2010) Dietary saponins of sea cucumber alleviate orotic acid-induced fatty liver in rats via PPARalpha and SREBP-1c signaling. Lipids Health Dis 9:25. doi:10.1186/1476-511X-9-25

    PubMed Central  PubMed  Google Scholar 

  38. Hong XZ, Li LD, Wu LM (2007) Effects of fenofibrate and xuezhikang on high-fat diet-induced non-alcoholic fatty liver disease. Clin Exp Pharmacol Physiol 34:27–35. doi:10.1111/j.1440-1681.2007.04547.x

    CAS  PubMed  Google Scholar 

  39. Kamada Y, Matsumoto H, Tamura S, Fukushima J, Kiso S, Fukui K, Igura T, Maeda N, Kihara S, Funahashi T, Matsuzawa Y, Shimomura I, Hayashi N (2007) Hypoadiponectinemia accelerates hepatic tumor formation in a nonalcoholic steatohepatitis mouse model. J Hepatol 47:556–564. doi:10.1016/j.jhep.2007.03.020

    CAS  PubMed  Google Scholar 

  40. Holland WL, Miller RA, Wang ZV, Sun K, Barth BM, Bui HH, Davis KE, Bikman BT, Halberg N, Rutkowski JM, Wade MR, Tenorio VM, Kuo MS, Brozinick JT, Zhang BB, Birnbaum MJ, Summers SA, Scherer PE (2011) Receptor-mediated activation of ceramidase activity initiates the pleiotropic actions of adiponectin. Nat Med 17:55–63. doi:10.1038/nm.2277

    CAS  PubMed Central  PubMed  Google Scholar 

  41. Yokota T, Oritani K, Takahashi I, Ishikawa J, Matsuyama A, Ouchi N, Kihara S, Funahashi T, Tenner AJ, Tomiyama Y, Matsuzawa Y (2000) Adiponectin, a new member of the family of soluble defense collagens, negatively regulates the growth of myelomonocytic progenitors and the functions of macrophages. Blood 96:1723–1732

    CAS  PubMed  Google Scholar 

  42. Ouchi N, Kihara S, Arita Y, Nishida M, Matsuyama A, Okamoto Y, Ishigami M, Kuriyama H, Kishida K, Nishizawa H, Hotta K, Muraguchi M, Ohmoto Y, Yamashita S, Funahashi T, Matsuzawa Y (2001) Adipocyte-derived plasma protein, adiponectin, suppresses lipid accumulation and class A scavenger receptor expression in human monocyte-derived macrophages. Circulation 103:1057–1063

    CAS  PubMed  Google Scholar 

  43. Wulster-Radcliffe MC, Ajuwon KM, Wang J, Christian JA, Spurlock ME (2004) Adiponectin differentially regulates cytokines in porcine macrophages. Biochem Biophys Res Commun 316:924–929. doi:10.1016/j.bbrc.2004.02.130

    CAS  PubMed  Google Scholar 

  44. Lira FS, Rosa JC, Pimentel GD, Seelaender M, Damaso AR, Oyama LM, do Nascimento CO (2012) Both adiponectin and interleukin-10 inhibit LPS-induced activation of the NF-kappaB pathway in 3T3-L1 adipocytes. Cytokine 57:98–106. doi:10.1016/j.cyto.2011.10.001

    CAS  PubMed  Google Scholar 

  45. Masaki T, Chiba S, Tatsukawa H, Yasuda T, Noguchi H, Seike M, Yoshimatsu H (2004) Adiponectin protects LPS-induced liver injury through modulation of TNF-alpha in KK-Ay obese mice. Hepatology 40:177–184. doi:10.1002/hep.20282

    CAS  PubMed  Google Scholar 

  46. Day CP (2006) From fat to inflammation. Gastroenterology 130:207–210. doi:10.1053/j.gastro.2005.11.017

    CAS  PubMed  Google Scholar 

  47. Videla LA, Rodrigo R, Araya J, Poniachik J (2004) Oxidative stress and depletion of hepatic long-chain polyunsaturated fatty acids may contribute to nonalcoholic fatty liver disease. Free Radic Biol Med 37:1499–1507. doi:10.1016/j.freeradbiomed.2004.06.033

    CAS  PubMed  Google Scholar 

  48. Tilg H, Diehl AM (2000) Cytokines in alcoholic and nonalcoholic steatohepatitis. N Engl J Med 343:1467–1476. doi:10.1056/NEJM200011163432007

    CAS  PubMed  Google Scholar 

  49. Kumada M, Kihara S, Ouchi N, Kobayashi H, Okamoto Y, Ohashi K, Maeda K, Nagaretani H, Kishida K, Maeda N, Nagasawa A, Funahashi T, Matsuzawa Y (2004) Adiponectin specifically increased tissue inhibitor of metalloproteinase-1 through interleukin-10 expression in human macrophages. Circulation 109:2046–2049. doi:10.1161/01.CIR.0000127953.98131.ED

    CAS  PubMed  Google Scholar 

  50. Wolf AM, Wolf D, Rumpold H, Enrich B, Tilg H (2004) Adiponectin induces the anti-inflammatory cytokines IL-10 and IL-1RA in human leukocytes. Biochem Biophys Res Commun 323:630–635. doi:10.1016/j.bbrc.2004.08.145

    CAS  PubMed  Google Scholar 

  51. Tsatsanis C, Zacharioudaki V, Androulidaki A, Dermitzaki E, Charalampopoulos I, Minas V, Gravanis A, Margioris AN (2005) Adiponectin induces TNF-alpha and IL-6 in macrophages and promotes tolerance to itself and other pro-inflammatory stimuli. Biochem Biophys Res Commun 335:1254–1263. doi:10.1016/j.bbrc.2005.07.197

    CAS  PubMed  Google Scholar 

  52. Arita Y, Kihara S, Ouchi N, Maeda K, Kuriyama H, Okamoto Y, Kumada M, Hotta K, Nishida M, Takahashi M, Nakamura T, Shimomura I, Muraguchi M, Ohmoto Y, Funahashi T, Matsuzawa Y (2002) Adipocyte-derived plasma protein adiponectin acts as a platelet-derived growth factor-BB-binding protein and regulates growth factor-induced common postreceptor signal in vascular smooth muscle cell. Circulation 105:2893–2898

    CAS  PubMed  Google Scholar 

  53. Yokota T, Meka CS, Kouro T, Medina KL, Igarashi H, Takahashi M, Oritani K, Funahashi T, Tomiyama Y, Matsuzawa Y, Kincade PW (2003) Adiponectin, a fat cell product, influences the earliest lymphocyte precursors in bone marrow cultures by activation of the cyclooxygenase-prostaglandin pathway in stromal cells. J Immunol 171:5091–5099

    CAS  PubMed  Google Scholar 

  54. Kamada Y, Tamura S, Kiso S, Matsumoto H, Saji Y, Yoshida Y, Fukui K, Maeda N, Nishizawa H, Nagaretani H, Okamoto Y, Kihara S, Miyagawa J, Shinomura Y, Funahashi T, Matsuzawa Y (2003) Enhanced carbon tetrachloride-induced liver fibrosis in mice lacking adiponectin. Gastroenterology 125:1796–1807

    CAS  PubMed  Google Scholar 

  55. Ding X, Saxena NK, Lin S, Xu A, Srinivasan S, Anania FA (2005) The roles of leptin and adiponectin: a novel paradigm in adipocytokine regulation of liver fibrosis and stellate cell biology. Am J Pathol 166:1655–1669. doi:10.1016/S0002-9440(10)62476-5

    CAS  PubMed Central  PubMed  Google Scholar 

  56. Bertolani C, Marra F (2008) The role of adipokines in liver fibrosis. Pathophysiology 15:91–101. doi:10.1016/j.pathophys.2008.05.001

    CAS  PubMed  Google Scholar 

  57. Wanninger J, Neumeier M, Bauer S, Weiss TS, Eisinger K, Walter R, Dorn C, Hellerbrand C, Schaffler A, Buechler C (2011) Adiponectin induces the transforming growth factor decoy receptor BAMBI in human hepatocytes. FEBS Lett 585:1338–1344. doi:10.1016/j.febslet.2011.04.003

    CAS  PubMed  Google Scholar 

  58. Handy JA, Fu PP, Kumar P, Mells JE, Sharma S, Saxena NK, Anania FA (2011) Adiponectin inhibits leptin signalling via multiple mechanisms to exert protective effects against hepatic fibrosis. Biochem J 440:385–395. doi:10.1042/BJ20102148

    CAS  PubMed Central  PubMed  Google Scholar 

  59. Wanninger J, Walter R, Bauer S, Eisinger K, Schaffler A, Dorn C, Weiss TS, Hellerbrand C, Buechler C (2011) MMP-9 activity is increased by adiponectin in primary human hepatocytes but even negatively correlates with serum adiponectin in a rodent model of non-alcoholic steatohepatitis. Exp Mol Pathol 91:603–607. doi:10.1016/j.yexmp.2011.07.001

    CAS  PubMed  Google Scholar 

  60. Hemmann S, Graf J, Roderfeld M, Roeb E (2007) Expression of MMPs and TIMPs in liver fibrosis—a systematic review with special emphasis on anti-fibrotic strategies. J Hepatol 46:955–975. doi:10.1016/j.jhep.2007.02.003

    CAS  PubMed  Google Scholar 

  61. Tomita K, Tamiya G, Ando S, Ohsumi K, Chiyo T, Mizutani A, Kitamura N, Toda K, Kaneko T, Horie Y, Han JY, Kato S, Shimoda M, Oike Y, Tomizawa M, Makino S, Ohkura T, Saito H, Kumagai N, Nagata H, Ishii H, Hibi T (2006) Tumour necrosis factor alpha signalling through activation of Kupffer cells plays an essential role in liver fibrosis of non-alcoholic steatohepatitis in mice. Gut 55:415–424. doi:10.1136/gut.2005.071118

    CAS  PubMed Central  PubMed  Google Scholar 

  62. Larsson SC, Wolk A (2007) Overweight, obesity and risk of liver cancer: a meta-analysis of cohort studies. Br J Cancer 97:1005–1008. doi:10.1038/sj.bjc.6603932

    CAS  PubMed Central  PubMed  Google Scholar 

  63. Ascha MS, Hanouneh IA, Lopez R, Tamimi TA, Feldstein AF, Zein NN (2010) The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. Hepatology 51:1972–1978. doi:10.1002/hep.23527

    PubMed  Google Scholar 

  64. Ezaki H, Yoshida Y, Saji Y, Takemura T, Fukushima J, Matsumoto H, Kamada Y, Wada A, Igura T, Kihara S, Funahashi T, Shimomura I, Tamura S, Kiso S, Hayashi N (2009) Delayed liver regeneration after partial hepatectomy in adiponectin knockout mice. Biochem Biophys Res Commun 378:68–72. doi:10.1016/j.bbrc.2008.10.176

    CAS  PubMed  Google Scholar 

  65. Adinolfi LE, Gambardella M, Andreana A, Tripodi MF, Utili R, Ruggiero G (2001) Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology 33:1358–1364. doi:10.1053/jhep.2001.24432

    CAS  PubMed  Google Scholar 

  66. Powell EE, Jonsson JR, Clouston AD (2005) Steatosis: co-factor in other liver diseases. Hepatology 42:5–13. doi:10.1002/hep.20750

    CAS  PubMed  Google Scholar 

  67. Adinolfi LE, Durante-Mangoni E, Zampino R, Ruggiero G (2005) Review article: hepatitis C virus-associated steatosis–pathogenic mechanisms and clinical implications. Aliment Pharmacol Ther 22(Suppl 2):52–55. doi:10.1111/j.1365-2036.2005.02597.x

    PubMed  Google Scholar 

  68. Goodman ZD, Ishak KG (1995) Histopathology of hepatitis C virus infection. Semin Liver Dis 15(1):70–81. doi:10.1055/s-2007-1007264

    CAS  PubMed  Google Scholar 

  69. Corbetta S, Redaelli A, Pozzi M, Bovo G, Ratti L, Redaelli E, Pellegrini C, Beck-Peccoz P, Spada A (2011) Fibrosis is associated with adiponectin resistance in chronic hepatitis C virus infection. Eur J Clin Invest 41:898–905. doi:10.1111/j.1365-2362.2011.02498.x

    CAS  PubMed  Google Scholar 

  70. Zografos TA, Liaskos C, Rigopoulou EI, Togousidis E, Makaritsis K, Germenis A, Dalekos GN (2008) Adiponectin: a new independent predictor of liver steatosis and response to IFN-alpha treatment in chronic hepatitis C. Am J Gastroenterol 103:605–614. doi:10.1111/j.1572-0241.2007.01729.x

    CAS  PubMed  Google Scholar 

  71. Sumie S, Kawaguchi T, Kuromatsu R, Takata A, Nakano M, Satani M, Yamada S, Niizeki T, Torimura T, Sata M (2011) Total and high molecular weight adiponectin and hepatocellular carcinoma with HCV infection. PLoS ONE 6:e26840. doi:10.1371/journal.pone.0026840

    CAS  PubMed Central  PubMed  Google Scholar 

  72. Khattab MA, Eslam M, Shatat M, Abd-Aalhalim H, Mousa YI, Samir F, Aly H, Shaker O, Shaker Y (2012) Changes in adipocytokines and insulin sensitivity during and after antiviral therapy for hepatitis C genotype 4. J Gastrointestin Liver Dis 21:59–65

    Google Scholar 

  73. Zografos TA, Rigopoulou EI, Liaskos C, Togousidis E, Zachou K, Gatselis N, Germenis A, Dalekos GN (2006) Alterations of leptin during IFN-alpha therapy in patients with chronic viral hepatitis. J Hepatol 44:848–855. doi:10.1016/j.jhep.2006.01.025

    CAS  PubMed  Google Scholar 

  74. Sebastiani G, Alberti A (2006) Non invasive fibrosis biomarkers reduce but not substitute the need for liver biopsy. World J Gastroenterol 12:3682–3694

    PubMed  Google Scholar 

  75. Bondini S, Kleiner DE, Goodman ZD, Gramlich T, Younossi ZM (2007) Pathologic assessment of non-alcoholic fatty liver disease. Clin Liver Dis 11:17–23, vii. doi:10.1016/j.cld.2007.02.002

    Google Scholar 

  76. Bugianesi E, Pagotto U, Manini R, Vanni E, Gastaldelli A, de Iasio R, Gentilcore E, Natale S, Cassader M, Rizzetto M, Pasquali R, Marchesini G (2005) Plasma adiponectin in nonalcoholic fatty liver is related to hepatic insulin resistance and hepatic fat content, not to liver disease severity. J Clin Endocrinol Metab 90:3498–3504. doi:10.1210/jc.2004-2240

    CAS  PubMed  Google Scholar 

  77. Krawczyk K, Szczesniak P, Kumor A, Jasinska A, Omulecka A, Pietruczuk M, Orszulak-Michalak D, Sporny S, Malecka-Panas E (2009) Adipohormones as prognostric markers in patients with nonalcoholic steatohepatitis (NASH). J Physiol Pharmacol 60(Suppl 3):71–75

    PubMed  Google Scholar 

  78. Targher G, Bertolini L, Rodella S, Lippi G, Franchini M, Zoppini G, Muggeo M, Day CP (2008) NASH predicts plasma inflammatory biomarkers independently of visceral fat in men. Obesity 16:1394–1399. doi:10.1038/oby.2008.64

    CAS  PubMed  Google Scholar 

  79. Turer AT, Browning JD, Ayers CR, Das SR, Khera A, Vega GL, Grundy SM, Scherer PE (2012) Adiponectin as an independent predictor of the presence and degree of hepatic steatosis in the Dallas Heart Study. J Clin Endocrinol Metab 97:E982–E986

    CAS  PubMed  Google Scholar 

  80. Polyzos SA, Toulis KA, Goulis DG, Zavos C, Kountouras J (2011) Serum total adiponectin in nonalcoholic fatty liver disease: a systematic review and meta-analysis. Metabolism 60:313–326. doi:10.1016/j.metabol.2010.09.003

    CAS  PubMed  Google Scholar 

  81. Targher G, Bertolini L, Rodella S, Zoppini G, Scala L, Zenari L, Falezza G (2006) Associations between plasma adiponectin concentrations and liver histology in patients with nonalcoholic fatty liver disease. Clin Endocrinol 64:679–683. doi:10.1111/j.1365-2265.2006.02527.x

    CAS  Google Scholar 

  82. Hui JM, Hodge A, Farrell GC, Kench JG, Kriketos A, George J (2004) Beyond insulin resistance in NASH: tNF-alpha or adiponectin? Hepatology 40:46–54. doi:10.1002/hep.20280

    CAS  PubMed  Google Scholar 

  83. Yokoyama H, Hirose H, Ohgo H, Saito I (2004) Inverse association between serum adiponectin level and transaminase activities in Japanese male workers. J Hepatol 41:19–24. doi:10.1016/j.jhep.2004.03.003

    CAS  PubMed  Google Scholar 

  84. Bugianesi E, Gentilcore E, Manini R, Natale S, Vanni E, Villanova N, David E, Rizzetto M, Marchesini G (2005) A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease. Am J Gastroenterol 100:1082–1090. doi:10.1111/j.1572-0241.2005.41583.x

    CAS  PubMed  Google Scholar 

  85. Wong VW, Hui AY, Tsang SW, Chan JL, Tse AM, Chan KF, So WY, Cheng AY, Ng WF, Wong GL, Sung JJ, Chan HL (2006) Metabolic and adipokine profile of Chinese patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 4:1154–1161. doi:10.1016/j.cgh.2006.06.011

    CAS  PubMed  Google Scholar 

  86. Wong VW, Wong GL, Choi PC, Chan AW, Li MK, Chan HY, Chim AM, Yu J, Sung JJ, Chan HL (2010) Disease progression of non-alcoholic fatty liver disease: a prospective study with paired liver biopsies at 3 years. Gut 59:969–974. doi:10.1136/gut.2009.205088

    Google Scholar 

  87. Pagano C, Soardo G, Esposito W, Fallo F, Basan L, Donnini D, Federspil G, Sechi LA, Vettor R (2005) Plasma adiponectin is decreased in nonalcoholic fatty liver disease. Eur J Endocrinol 152:113–118

    CAS  PubMed  Google Scholar 

  88. Sadik NA, Ahmed A, Ahmed S (2012) The significance of serum levels of adiponectin, leptin, and hyaluronic acid in hepatocellular carcinoma of cirrhotic and noncirrhotic patients. Hum Exp Toxicol 31:311–321

    CAS  PubMed  Google Scholar 

  89. Neumeier M, Hellerbrand C, Gabele E, Buettner R, Bollheimer C, Weigert J, Schaffler A, Weiss TS, Lichtenauer M, Scholmerich J, Buechler C (2006) Adiponectin and its receptors in rodent models of fatty liver disease and liver cirrhosis. World J Gastroenterol 12:5490–5494

    CAS  PubMed  Google Scholar 

  90. Tietge UJ, Boker KH, Manns MP, Bahr MJ (2004) Elevated circulating adiponectin levels in liver cirrhosis are associated with reduced liver function and altered hepatic hemodynamics. Am J Physiol Endocrinol Metab 287:E82–E89. doi:10.1152/ajpendo.00494.2003

    CAS  PubMed  Google Scholar 

  91. Kaser S, Moschen A, Kaser A, Ludwiczek O, Ebenbichler CF, Vogel W, Jaschke W, Patsch JR, Tilg H (2005) Circulating adiponectin reflects severity of liver disease but not insulin sensitivity in liver cirrhosis. J Intern Med 258:274–280. doi:10.1111/j.1365-2796.2005.01543.x

    CAS  PubMed  Google Scholar 

  92. Salman TA, Allam N, Azab GI, Shaarawy AA, Hassouna MM, El-Haddad OM (2010) Study of adiponectin in chronic liver disease and cholestasis. Hepatol Int 4:767–774. doi:10.1007/s12072-010-9216-0

    PubMed Central  PubMed  Google Scholar 

  93. Tacke F, Wustefeld T, Horn R, Luedde T, Srinivas Rao A, Manns MP, Trautwein C, Brabant G (2005) High adiponectin in chronic liver disease and cholestasis suggests biliary route of adiponectin excretion in vivo. J Hepatol 42:666–673. doi:10.1016/j.jhep.2004.12.024

    CAS  PubMed  Google Scholar 

  94. Zelber-Sagi S, Ratziu V, Zvibel I, Goldiner I, Blendis L, Morali G, Halpern Z, Oren R (2012) The association between adipocytokines and biomarkers for nonalcoholic fatty liver disease-induced liver injury: a study in the general population. Eur J Gastroenterol Hepatol 24:262–269. doi:10.1097/MEG.0b013e32834f15dd

    CAS  PubMed  Google Scholar 

  95. Koehler E, Swain J, Sanderson S, Krishnan A, Watt K, Charlton M (2012) Growth hormone, dehydroepiandrosterone and adiponectin levels in non-alcoholic steatohepatitis: an endocrine signature for advanced fibrosis in obese patients. Liver Int 32:279–286. doi:10.1111/j.1478-3231.2011.02637.x

    CAS  PubMed  Google Scholar 

  96. Lemoine M, Ratziu V, Kim M, Maachi M, Wendum D, Paye F, Bastard JP, Poupon R, Housset C, Capeau J, Serfaty L (2009) Serum adipokine levels predictive of liver injury in non-alcoholic fatty liver disease. Liver Int 29:1431–1438. doi:10.1111/j.1478-3231.2009.02022.x

    CAS  PubMed  Google Scholar 

  97. Shimada M, Kawahara H, Ozaki K, Fukura M, Yano H, Tsuchishima M, Tsutsumi M, Takase S (2007) Usefulness of a combined evaluation of the serum adiponectin level, HOMA-IR, and serum type IV collagen 7S level to predict the early stage of nonalcoholic steatohepatitis. Am J Gastroenterol 102:1931–1938. doi:10.1111/j.1572-0241.2007.01322.x

    CAS  PubMed  Google Scholar 

  98. Younossi ZM, Jarrar M, Nugent C, Randhawa M, Afendy M, Stepanova M, Rafiq N, Goodman Z, Chandhoke V, Baranova A (2008) A novel diagnostic biomarker panel for obesity-related nonalcoholic steatohepatitis (NASH). Obes Surg 18:1430–1437. doi:10.1007/s11695-008-9506-y

    PubMed  Google Scholar 

  99. Kim SM, Cho GJ, Yannakoulia M, Hwang TG, Kim IH, Park EK, Mantzoros CS (2011) Lifestyle modification increases circulating adiponectin concentrations but does not change vaspin concentrations. Metabolism 60:1294–1299. doi:10.1016/j.metabol.2011.01.013

    CAS  PubMed  Google Scholar 

  100. Moschen AR, Molnar C, Geiger S, Graziadei I, Ebenbichler CF, Weiss H, Kaser S, Kaser A, Tilg H (2010) Anti-inflammatory effects of excessive weight loss: potent suppression of adipose interleukin 6 and tumour necrosis factor alpha expression. Gut 59:1259–1264. doi:10.1136/gut.2010.214577

    CAS  PubMed  Google Scholar 

  101. Lang HF, Chou CY, Sheu WH, Lin JY (2011) Weight loss increased serum adiponectin but decreased lipid levels in obese subjects whose body mass index was lower than 30 kg/m(2). Nutr Res 31:378–386. doi:10.1016/j.nutres.2011.04.004

    CAS  PubMed  Google Scholar 

  102. Summer SS, Brehm BJ, Benoit SC, D’Alessio DA (2011) Adiponectin changes in relation to the macronutrient composition of a weight-loss diet. Obesity 19:2198–2204. doi:10.1038/oby.2011.60

    CAS  PubMed  Google Scholar 

  103. Fukushima J, Kamada Y, Matsumoto H, Yoshida Y, Ezaki H, Takemura T, Saji Y, Igura T, Tsutsui S, Kihara S, Funahashi T, Shimomura I, Tamura S, Kiso S, Hayashi N (2009) Adiponectin prevents progression of steatohepatitis in mice by regulating oxidative stress and Kupffer cell phenotype polarization. Hepatol Res 39:724–738. doi:10.1111/j.1872-034X.2009.00509.x

    CAS  PubMed  Google Scholar 

  104. Xu A, Wang Y, Keshaw H, Xu LY, Lam KS, Cooper GJ (2003) The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice. J Clin Invest 112:91–100. doi:10.1172/JCI17797

    CAS  PubMed Central  PubMed  Google Scholar 

  105. Pajvani UB, Du X, Combs TP, Berg AH, Rajala MW, Schulthess T, Engel J, Brownlee M, Scherer PE (2003) Structure-function studies of the adipocyte-secreted hormone Acrp30/adiponectin. Implications fpr metabolic regulation and bioactivity. J Biol Chem 278:9073–9085. doi:10.1074/jbc.M207198200

    CAS  PubMed  Google Scholar 

  106. Pajvani UB, Hawkins M, Combs TP, Rajala MW, Doebber T, Berger JP, Wagner JA, Wu M, Knopps A, Xiang AH, Utzschneider KM, Kahn SE, Olefsky JM, Buchanan TA, Scherer PE (2004) Complex distribution, not absolute amount of adiponectin, correlates with thiazolidinedione-mediated improvement in insulin sensitivity. J Biol Chem 279:12152–12162. doi:10.1074/jbc.M311113200

    CAS  PubMed  Google Scholar 

  107. Kobayashi H, Ouchi N, Kihara S, Walsh K, Kumada M, Abe Y, Funahashi T, Matsuzawa Y (2004) Selective suppression of endothelial cell apoptosis by the high molecular weight form of adiponectin. Circ Res 94:e27–e31. doi:10.1161/01.RES.0000119921.86460.37

    CAS  PubMed  Google Scholar 

  108. Xu A, Wang H, Hoo RL, Sweeney G, Vanhoutte PM, Wang Y, Wu D, Chu W, Qin G, Lam KS (2009) Selective elevation of adiponectin production by the natural compounds derived from a medicinal herb alleviates insulin resistance and glucose intolerance in obese mice. Endocrinology 150:625–633. doi:10.1210/en.2008-0999

    CAS  PubMed Central  PubMed  Google Scholar 

  109. Promrat K, Lutchman G, Uwaifo GI, Freedman RJ, Soza A, Heller T, Doo E, Ghany M, Premkumar A, Park Y, Liang TJ, Yanovski JA, Kleiner DE, Hoofnagle JH (2004) A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. Hepatology 39:188–196. doi:10.1002/hep.20012

    CAS  PubMed  Google Scholar 

  110. Belfort R, Harrison SA, Brown K, Darland C, Finch J, Hardies J, Balas B, Gastaldelli A, Tio F, Pulcini J, Berria R, Ma JZ, Dwivedi S, Havranek R, Fincke C, DeFronzo R, Bannayan GA, Schenker S, Cusi K (2006) A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med 355:2297–2307. doi:10.1056/NEJMoa060326

    CAS  PubMed  Google Scholar 

  111. Idilman R, Mizrak D, Corapcioglu D, Bektas M, Doganay B, Sayki M, Coban S, Erden E, Soykan I, Emral R, Uysal AR, Ozden A (2008) Clinical trial: insulin-sensitizing agents may reduce consequences of insulin resistance in individuals with non-alcoholic steatohepatitis. Aliment Pharmacol Ther 28:200–208. doi:10.1111/j.1365-2036.2008.03723.x

    CAS  PubMed  Google Scholar 

  112. Sanyal AJ, Chalasani N, Kowdley KV, McCullough A, Diehl AM, Bass NM, Neuschwander-Tetri BA, Lavine JE, Tonascia J, Unalp A, Van Natta M, Clark J, Brunt EM, Kleiner DE, Hoofnagle JH, Robuck PR, Nash CRN (2010) Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med 362:1675–1685. doi:10.1056/NEJMoa0907929

    CAS  PubMed Central  PubMed  Google Scholar 

  113. Yki-Jarvinen H (2004) Thiazolidinediones. N Engl J Med 351:1106–1118. doi:10.1056/NEJMra041001

    PubMed  Google Scholar 

  114. Maeda N, Takahashi M, Funahashi T, Kihara S, Nishizawa H, Kishida K, Nagaretani H, Matsuda M, Komuro R, Ouchi N, Kuriyama H, Hotta K, Nakamura T, Shimomura I, Matsuzawa Y (2001) PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes 50:2094–2099

    CAS  PubMed  Google Scholar 

  115. Savage DB, Tan GD, Acerini CL, Jebb SA, Agostini M, Gurnell M, Williams RL, Umpleby AM, Thomas EL, Bell JD, Dixon AK, Dunne F, Boiani R, Cinti S, Vidal-Puig A, Karpe F, Chatterjee VK, O’Rahilly S (2003) Human metabolic syndrome resulting from dominant-negative mutations in the nuclear receptor peroxisome proliferator-activated receptor-gamma. Diabetes 52:910–917

    CAS  PubMed  Google Scholar 

  116. Nawrocki AR, Rajala MW, Tomas E, Pajvani UB, Saha AK, Trumbauer ME, Pang Z, Chen AS, Ruderman NB, Chen H, Rossetti L, Scherer PE (2006) Mice lacking adiponectin show decreased hepatic insulin sensitivity and reduced responsiveness to peroxisome proliferator-activated receptor gamma agonists. J Biol Chem 281:2654–2660. doi:10.1074/jbc.M505311200

    CAS  PubMed  Google Scholar 

  117. Fasshauer M, Klein J, Neumann S, Eszlinger M, Paschke R (2002) Hormonal regulation of adiponectin gene expression in 3T3-L1 adipocytes. Biochem Biophys Res Commun 290:1084–1089. doi:10.1006/bbrc.2001.6307

    CAS  PubMed  Google Scholar 

  118. Dubuisson O, Dhurandhar EJ, Krishnapuram R, Kirk-Ballard H, Gupta AK, Hegde V, Floyd E, Gimble JM, Dhurandhar NV (2011) PPARgamma-independent increase in glucose uptake and adiponectin abundance in fat cells. Endocrinology 152:3648–3660. doi:10.1210/en.2011-0225

    CAS  PubMed Central  PubMed  Google Scholar 

  119. Rubio-Guerra AF, Vargas-Robles H, Vargas-Ayala G, Rodriguez-Lopez L, Castro-Serna D, Escalante-Acosta BA (2011) Impact of trandolapril therapy and its combination with a calcium channel blocker on plasma adiponectin levels in patients with type 2 diabetes and hypertension. Ther Adv Cardiovasc Dis 5:193–197. doi:10.1177/1753944711415307

    CAS  PubMed  Google Scholar 

  120. Yamagishi S, Nakamura K, Matsui T (2007) Potential utility of telmisartan, an angiotensin II type 1 receptor blocker with peroxisome proliferator-activated receptor-gamma (PPAR-gamma)-modulating activity for the treatment of cardiometabolic disorders. Curr Mol Med 7:463–469

    CAS  PubMed  Google Scholar 

  121. Kurtz TW (2005) Treating the metabolic syndrome: telmisartan as a peroxisome proliferator-activated receptor-gamma activator. Acta Diabetol 42(Suppl 1):S9–S16. doi:10.1007/s00592-005-0176-0

    CAS  PubMed  Google Scholar 

  122. Takagi H, Umemoto T (2012) Telmisartan increases adiponectin levels: a meta-analysis and meta-regression of randomized head-to-head trials. Int J Cardiol 155:448–451. doi:10.1016/j.ijcard.2011.11.071

    PubMed  Google Scholar 

Download references

Conflict of interest

The authors declare that they have no conflict of interest.

Author information

Authors and Affiliations

  1. Department of Medicine and Research Laboratory of Internal Medicine, Thessaly University Medical School, Biopolis, 41110, Larissa, Thessaly, Greece

    Nikolaos K. Gatselis, George Ntaios, Konstantinos Makaritsis & George N. Dalekos

Authors
  1. Nikolaos K. Gatselis
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. George Ntaios
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Konstantinos Makaritsis
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. George N. Dalekos
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to George N. Dalekos.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gatselis, N.K., Ntaios, G., Makaritsis, K. et al. Adiponectin: a key playmaker adipocytokine in non-alcoholic fatty liver disease. Clin Exp Med 14, 121–131 (2014). https://doi.org/10.1007/s10238-012-0227-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10238-012-0227-0

Keywords

Search

Navigation